Abraxis Bioscience Dismisses Patent Infringement Complaint Against Sun Pharma’s SPARC
Abraxis Bioscience dropping patent infringement charges against SPARC paves the way for launch of Paclitaxel injection, CEO says.
Sun Pharma Advanced Research Company Ltd. on Monday said Abraxis Bioscience LLC has dismissed the patent infringement complaint filed against the company.
"Abraxis Biosciences LLC has dismissed the patent infringement complaint filed against Sun Pharma Advanced Research regarding SPARC's New Drug Application for Paclitaxel Injection Concentrate for Suspension," the company said in a fling.
"We are very pleased that Abraxis Bioscience LLC has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals," SPARC's Chief Executive Officer Anil Raghavan said.
SPARC will also inform the U.S. Food and Drug Administration of the dismissal of the complaint to vacate the 30-month stay, the filing added.